CAR-T helps some stiff person syndrome patients resume work
Mayo Clinic neurologists reported early JAMA Neurology results for an immunotherapy already used in cancer, while saying durability remains unknown.

Mayo Clinic neurologists reported Nov. 9 in JAMA Neurology that CAR-T cell therapy improved function in some patients with stiff person syndrome, a rare autoimmune condition affecting the central nervous system.
The trial matters because existing treatments may ease symptoms but rarely restore prior function, Anastasia Zekeridou of Mayo Clinic said; one participant reported walking for seven minutes on a treadmill after treatment.
Stiff person syndrome can cause severe body rigidity and painful muscle spasms. Céline Dion said in December 2022 that she had been diagnosed with the disorder, which she said affected “every aspect of my daily life”, including her voice.
CAR-T cell therapy is already used in some cancers. In this trial, doctors removed patients’ own T cells, a type of immune cell, and engineered them to target cells believed to drive the disease, according to The Guardian Health report.
“What was most striking was the degree of improvement we saw in some patients,” Zekeridou, a neurologist and researcher at Mayo Clinic in Rochester, said. “With existing treatments, we may be able to improve symptoms but we very rarely see patients return to their previous level of function. These early results are very encouraging and the key question now is whether those improvements will be sustained over time.”
Jonathan Walden, a trial participant, had needed family help for walking and basic daily activities, according to the report. After CAR-T therapy, he said: “I can go to work every single day. I can do everything I did before.
I go hunting; I can go fishing. I have not had one episode since receiving treatment.”
Another participant, Shari St Germain, had severe leg cramps, walking problems, muscle rigidity and falls, according to the report. She said every day feels “better and better” after treatment.
The study cannot show from the reported details how long the benefit will last, whether all patients with stiff person syndrome would respond, or how the risks of CAR-T compare with existing care. The Guardian report did not give the trial size, duration, comparison group, funding or conflict disclosures.
Sean Pittock, chair of neurology at Mayo Clinic, said the results suggest CAR-T may have uses beyond cancer and could be relevant to other immune-mediated neurologic conditions, while adding: “There is still much we need to learn.” Yasmin Sheikh of Anthony Nolan, a blood cancer charity not involved in the trial, said the research adds evidence that CAR-T therapies could have applications beyond blood cancer.
Source: news report, The Guardian Health, Nov. 9, 2026.
Atlas360 reports health research and does not provide medical advice.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Plant-based dairy swaps may lower iodine intake
- Adults 50 to 64 reach 7.5% heavy-drinking rate
- Cyclospora outbreak inquiry puts FDA testing under review
- Taco Bell lettuce linked to parasite outbreak in US cases
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

